Replies to post #234904 on Biotech Values

[DewDiligence]

YMAB resubmits Omburtamab BLA:

https://www.globenewswire.com/news-release/2022/04/01/2414852/0/en/Y-mAbs-Announces-Submission-of-Omburtamab-Biologics-License-Application-to-FDA.html

The 18-month turnaround time involved both clinical and CMC issues specified in the CRL.